Tatratrial s.r.o.
- Address
- Namestie 1. Maja 11, 048 01 Rožňava, Slovakia
Nutritional and Metabolic Diseases
At Tatratrial s.r.o. in Roznava, clinical research in Nutritional and Metabolic Diseases focuses on conditions that affect how the body processes energy and nutrients, with a strong emphasis on metabolism and related organ complications.
- Research in chronic kidney disease with high proteinuria to explore better ways to slow kidney function decline
- Studies in severe hypertriglyceridemia aimed at improving control of very high blood fat levels
These trials are designed to test new treatment approaches and evaluate how effectively they can improve outcomes for patients with metabolic disorders.
Metabolism
The site’s Metabolism research is centered on disorders of lipid and kidney-related regulation, reflecting a practical clinical focus on diseases where metabolic imbalance drives serious health risks.
- Evaluation of therapies for chronic kidney disease and high proteinuria to support kidney protection
- Investigation of treatment options for severe hypertriglyceridemia to reduce fasting serum triglyceride levels
Overall, the studies are assessing whether emerging therapies can offer stronger disease control and better long-term management than current standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Arrowhead Pharmaceuticals Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Arrowhead Pharmaceuticals Inc.4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tatratrial s.r.o.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 4 | Unknown | 2024-11-04 | 2025-12-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.